Company
Pharvaris N.V.
Headquarters: Leiden, Netherlands
Employees: 17
CEO: Mr. Berndt Axel Edvard Modig CPA, M.B.A., MBA
Market Cap
€859.0 Million
EUR as of July 1, 2025
US$1.01 Billion
Pharvaris N.V. Categories
Netherlands Healthcare BiotechnologyNetherlands Healthcare Netherlands Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $309.91 B |
| Vertex Pharmaceuticals Incorporated | $117.36 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $59.14 B |
| Marinomed Biotech AG | $58.56 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Detailed Description
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks; and PHVS719, a prophylactic extended-release tablet for HAE patients. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is headquartered in Leiden, the Netherlands.
Financials
| Last Financial Reports Date | March 31, 2025 |
| Revenue TTM | €0 |
| EBITDA | €-159,490,880 |
| Gross Profit TTM | €0 |
| Profit Margin | 0.00% |
| Operating Margin | 0.00% |
| Quarterly Revenue Growth | % |
Stocks & Indices
Pharvaris N.V. has the following listings and related stock indices.
Stock: FSX: 9EN wb_incandescent